## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.8% below STRENGTH zone (4.0-10.0%); PEG 2.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($111.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Channing Capital Management LLC Decreases Position in Elanco Animal Health Incorporated $ELAN**
- Source: MarketBeat | 20251205T041225 | Neutral | Relevance: 71%
- Channing Capital Management LLC reduced its stake in Elanco Animal Health Incorporated by 22.3%, selling 182,357 shares and retaining 634,770 shares valued at approximately $9.07 million. Despite this, analysts have become more positive on Elanco with several upgrades and price target increases, leading to a "Moderate Buy" consensus. The company recently surpassed quarterly earnings and revenue estimates and issued positive FY2025 guidance, with its stock trading near its 52-week high.

**2. How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?**
- Source: Markets Financial Content | 20251204T022900 | Neutral | Relevance: 71%
- IDEXX Laboratories (IDXX) is a global leader in veterinary diagnostics, consistently outperforming the Health Care Select Sector SPDR Fund (XLV) and rival Zoetis Inc. (ZTS) over several periods. The company's strong performance is driven by a diversified product ecosystem, recurring revenue model, and robust R&D, leading to increased full-year guidance and a "Moderate Buy" consensus rating from analysts.

**3. How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?**
- Source: Markets Financial Content | 20251204T022900 | Somewhat-Bearish | Relevance: 63%
- IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, has shown strong stock performance, outperforming the Health Care Select Sector SPDR Fund (XLV) over the past three months, year-to-date, and the last 52 weeks. The company's Q3 results exceeded expectations, leading to raised full-year guidance and highlighting its robust business model and market position. Despite strong performance, analysts maintain a cautiously optimistic "Moderate Buy" rating with a price target suggesting further upside.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 5)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |
| 2025-11-18 | Stifel | $130 | $140 | -7% |
| 2025-11-12 | BTIG | $160 | $200 | -20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |
| 2025-11-18 | Stifel | main | Hold |
| 2025-11-12 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 21.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.37 elevated, pricing in significant growth expectations. Forward P/E 17.5x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Analyst sentiment negative (5 target cuts vs 0 raises). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.37 |
| Forward P/E | 17.5 |
| Current P/E | 18.7 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.5% to -4.8% (-7.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.79x), long-term trend not supportive. MACD histogram positive (0.60), confirming momentum. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.77% (CS: 13) | Weak |
| RSI_14 | 33.8 | Neutral |
| MACD Histogram | 0.60 | Bullish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.885x | Below |
| vs SMA200 | 0.785x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $118.65
- **Stop Loss:** $111.77 (5.8% risk)
- **Target:** $125.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $8,542.80
- **Portfolio %:** 8.54%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*